Mentioned:
NVO LLY +0.65%
Novo Nordisk is on the leading edge of GLP-1 drugs for obesity. And they’re making pharmaceutical history in America in the process.
What’s happening:
- Novo Nordisk (NYSE: NVO) has been granted regulatory approval from the United States Food and Drug Administration for their Wegovy GLP-1 pill for weight loss
Why it matters:
- This is the first approval in American history from the Food and Drug Administration for a GLP-1 oral pill for obesity
Going deeper:
- Novo Nordisk’s Wegovy oral pill uses the same active ingredients as the injectable versions of both Wegovy and Ozempic and is only required to be taken once per day
- The Wegovy oral pill also has shown clinical evidence of being effective in reducing the risks of heart attacks and strokes in individuals who are obese or overweight
The intrigue:
- Eli Lilly (NYSE: LLY) has also completed Phase III clinical trials for their own GLP-1 oral pill for weight loss and is aiming to win a formal approval from the United States Food and Drug Administration imminently
